DNA X, Inc. Cash Flow Statement
SONM|6 years of annual SEC 10-K data (FY2019-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
DNA X, Inc. used $4M in operating cash flow and negative free cash flow of $4M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Income | -$90.0K | -$14.1M | -$38.6M | -$29.9M | -$25.8M | $1.3M |
| Depreciation & Amortization | $2.2M | $2.4M | $2.1M | $2.7M | $3.5M | $1.9M |
| Operating Cash Flow | -$4.1M | -$12.4M | -$38.5M | -$10.6M | -$33.5M | $3.9M |
| Capital Expenditures | $36.0K | $8.0K | $46.0K | $11.0K | $992.0K | $787.0K |
| Free Cash Flow | -$4.1M | -$12.4M | -$38.5M | -$10.6M | -$34.5M | $3.1M |
| FCF Margin | -4.4% | -17.7% | -70.6% | -16.5% | -29.7% | 2.3% |